Mechanism research of dexmedetomidine in the treatment of postherpetic neuralgia by promoting MDSC apoptosis and inhibiting p75

Phase 4

• Conditions: postherpetic neuralgia

• Registration Number: ITMCTR1900002439
• Lead Sponsor: Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) those who meet the diagnostic criteria for postherpetic neuralgia
(2) aged 18 to 80 years;
(3) body mass index (BMI) ranged from 18.0 to 25.0 (including 18.0 years old and 25.0 years old);
(4) VAS score of 4-10 points (including 4 points and 10 points);
(5) no satisfactory remission for at least 1 month after conservative pain treatment (e.g., antidepressants, anticonvulsants, tramadol, opioids, nerve block or damage, radiofrequency conditioning or damage);
(6) voluntarily participate in the study and have signed the informed consent.

Exclusion Criteria

(1) people who are known to be allergic to dexmedetomidine and ketorolac amantinol;
(2) inability to cooperate, such as lethargy, coma, confusion, delirium;
(3) having a history of alcohol or drug abuse;
(4) participants who have participated in other clinical trials within 12 weeks prior to or before the trial;
(5) patients with pain syndrome (such as complex regional pain syndrome, spinal cord injury, diabetic multiple neuropathy, fibromyalgia);
(6) patients with severe systemic diseases (including hypertension grade 2 or above, diabetes, myasthenia gravis, severe renal impairment, severe pulmonary dysfunction, shock, severe liver dysfunction, acute heart failure);
(7) patients with infectious diseases (i.e. HIV, hepatitis b, syphilis);
(8) severely infected;
(9) patients with malignant tumors;
(10) mental disorders (such as somatization disorders, schizophrenia, mania);
(11) resting heart rate < 55 times/min or > 100 times/min after ecg screening.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Myeloid-derived suppressor cells;apolipoprotein E;T cell;

Secondary Outcome Measures

Name	Time	Method
Visual analogue score value;Depression score;